Skip to Content

Implant-Associated Anaplastic Large Cell Lymphoma

Our Approach

MD Anderson's Breast Center cares for more patients with breast implant-associated anaplastic large cell lymphoma (ALCL) than almost any other center in the United States. You can be sure you are being cared for by renowned physicians with the highest levels of experience and skill.

A team of more than 30 medical oncologists, Plastic and oncologic surgeons, radiation oncologists, and pathologists – all experts in their fields and ALCL – work together closely to customize the best treatment for you. A specially trained support team is part of each group.

Groundbreaking Research

MD Anderson researchers are pioneering remarkable advances to give you the best treatment for implant-associated ALCL. Areas of study include:

  • More-precise ways to diagnose implant-associated ALCL
  • Radiation and chemotherapy clinical trials for advanced disease
  • Novel targeted agents that help your body fight the disease

We constantly test new boundaries with research. Because of this, we can offer many clinical trials (research studies) of new treatments that are not available at other centers. In fact, the dedicated implant-associated ALCL research program at MD Anderson is one of few in the world.

And at MD Anderson you're surrounded by the strength of one of the nation's foremost comprehensive cancer centers. We have all the support and wellness services needed to treat the whole person – not just the disease.

If you have been diagnosed with implant-associated ALCL, it's important to be seen by expert doctors. Call 1-877-632-6789 to make an appointment or request an appointment online.

Why Choose MD Anderson?

  • Experts with extensive knowledge of treatments for implant-associated ALCL, an extremely rare cancer
  • Surgical techniques that maximize treatment outcomes while minimizing physical impacts
  • Access to breast reconstruction after treatment
  • Radiation and targeted chemotherapies for patients with advanced disease
  • Pathologists with experience in diagnosing implant-associated anaplastic large cell lymphoma

Implant Associated ALCL Knowledge Center

Treatment at MD Anderson

Implant associated ALCL is treated in our: 

Find Your MD Anderson Location

Breast Implant-Associated ALCL Facts

According to the U.S. Food and Drug Administration (FDA), less than one hundred people in the United States have been diagnosed with breast implant-associated ALCL, an extremely rare cancer.

Although implant-associated ALCL is extremely rare, the FDA believes that women with breast implants may have a very small but increased risk of developing this disease in the tissue capsule the body forms around an implant over time. ALCL may also be found in the lymph nodes and the skin.

At this time, data appears to indicate that the incidence of ALCL is very low, even in breast implant patients and is estimated to be between 1 in 70,000 to 1 in 500,000. Currently, it is not possible to identify a type of breast implant (silicone, saline or polyurethane) or a reason for the implant (reconstruction versus aesthetic augmentation) that is associated with a smaller or greater risk.

Overall, lymphomas of any type that occur in the breast are rare, accounting for only 1 to 2% of all non-Hodgkin's lymphomas. Most breast lymphomas have a B-cell phenotype. However, implant-associated ALCL has a T-cell phenotype.

Implant-associated ALCL tends to remain confined around the breast implant. Most patients have a good prognosis when they receive the appropriate treatment.

If you have been diagnosed with implant-associated ALCL, it's important to be seen by expert doctors. Call 1-877-632-6789 to make an appointment or request an appointment online.

© 2015 The University of Texas MD Anderson Cancer Center